|
|
Article: Research Suggests Trileptal as Monotherapy May Benefit Patients Suffering From Generalized Tonic-Clonic Seizures.
- Article from:
- Ascribe Higher Education News Service
- Article date:
- October 9, 2002
CopyrightCOPYRIGHT 2002 AScribe. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Feinstein Kean Healthcare
MADRID, Oct. 9 (AScribe Newswire) -- According to data presented today at the 5th European Congress on Epileptology, the anti-epileptic drug Trileptal (R) (oxcarbazepine, Novartis Pharmaceuticals Corporation), when used as monotherapy (used alone), was associated with a reduction in generalized tonic-clonic seizures (GTCS). A meta-analysis of data from five multi-center, double-blind, active-control trials involving 266 patients (149 Trileptal, 117 active control) over an 11-14 month period was conducted. The research found that 62 percent of patients receiving Trileptal monotherapy had no generalized tonic-clonic seizures for ...